1-4 of 4
Luminita Rusen, MD
Close
Sort by
Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD
Journal: Blood
Blood (2016) 128 (22): 1410.
https://doi.org/10.1182/blood.V128.22.1410.1410
Published: 2016
Journal Articles

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Jerzy Windyga, MD, PhD, Toshko Lissitchkov, MD, PhD, Oleksandra Stasyshyn, MD, Vasily Mamonov, MD, Luminita Rusen, MD, PhD, José Luis Lamas, MD, Myungshin Oh, PhD, Miranda Chapman, Sandor Fritsch, PhD, Borislava G Pavlova, PhD, Wing Yen Wong, MD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2012) 120 (21): 2222.
https://doi.org/10.1182/blood.V120.21.2222.2222
Published: 2012
Journal Articles

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, PhD, Amanda C. O’Brien, Brooke Hayward, SM, Steven Arkin, MD, David A. Roth, MD
Journal: Blood
Blood (2008) 112 (11): 1229.
https://doi.org/10.1182/blood.V112.11.1229.1229
Published: 2008
Journal Articles

Efficacy and Safety of ReFacto AF for Surgical Hemostasis in Previously Treated Patients with Severe Hemophilia A.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, Mona El-Hashimy, MD, David A. Roth, MD, Steven Arkin, MD
Journal: Blood
Blood (2007) 110 (11): 3960.
https://doi.org/10.1182/blood.V110.11.3960.3960
Published: 2007